VIVUS, Inc. (NASDAQ: VVUS), a pharmaceutical company, is focused on developing and commercializing next-generation therapeutic products designed to target obesity and sexual health. The potential market for obesity ranges from $5 billion to $10 billion annually according to speculating analysts, while the potential market for an effective diabetes therapy that causes weight loss is in excess of $2 billion. The indications targeted by VIVUS’ sexual health products each represent a potential market of more than $1 billion per annum. For further information, visit the Company’s web site at www.vivus.com.
- 18 years ago
QualityStocks
VIVUS, Inc. (NASDAQ: VVUS)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Why TruGolf Holdings Inc. (NASDAQ: TRUG) Is ‘One to Watch’
TruGolf (NASDAQ: TRUG) is pursuing a strategic expansion into blockchain-based financial infrastructure through its pending…
-
QualityStocksNewsBreaks – Versus Systems Inc. (NASDAQ: VS) Brings Interactive Experiences to Major Sports and Entertainment Audiences
Versus Systems (NASDAQ: VS) uses gamification and audience engagement technology to help brands, sports teams,…
-
QualityStocksNewsBreaks – BOXABL Inc. (NASDAQ: BXBL) Builds Momentum with Potential 1,500-Home Pipeline
BOXABL (NASDAQ: BXBL) has signed a multiyear purchase agreement with LC Vegas Acquisitions, LLC for…